ARS Pharmaceuticals (ARS Pharmaceuticals) Change In Other Working Capital : $0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Change In Other Working Capital?

ARS Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Mar. 2024 was $0.03 Mil. It means ARS Pharmaceuticals's Other Working Capital increased by $0.03 Mil from Dec. 2023 to Mar. 2024 .

ARS Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-3.12 Mil. It means ARS Pharmaceuticals's Other Working Capital declined by $3.12 Mil from Dec. 2022 to Dec. 2023 .

ARS Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for ARS Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Change In Other Working Capital Chart

ARS Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

6.96

-2.50

-1.28

-3.12

ARS Pharmaceuticals Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial							-3.13	-0.01	-	0.03	0.03

ARS Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

ARS Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ARS Pharmaceuticals (ARS Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130

Website

https://www.ars-pharma.com

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy (previously referred to as ARS-1) for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Executives

Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laura Shawver	director, officer: Chief Executive Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033